Regeneron Pharmaceuticals Inc
XBER:RGO

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
XBER:RGO
Watchlist
Price: 128.94 EUR 0.71% Market Closed
Market Cap: 13.9B EUR

Operating Margin
Regeneron Pharmaceuticals Inc

28.9%
Current
37%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
28.9%
=
Operating Profit
4.1B
/
Revenue
14.1B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.7B USD
29%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
330.5B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164.4B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
137.2B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
128.5B AUD
26%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
42.4B USD
-5%

Regeneron Pharmaceuticals Inc
Glance View

In the vibrant world of biotechnology, Regeneron Pharmaceuticals Inc. emerged as a powerhouse by meticulously weaving together science and medicine. Founded in 1988 by a visionary team, including celebrated scientists Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron was created with an ambitious mission to harness the power of biology to bring innovative medicines to patients. The company began its journey with a strong emphasis on research and development, evolving its unique approach to drug discovery focused on the rapid and precise identification of biologically relevant targets. With a strategic location at the heart of New York's biotechnology valley, Regeneron thrived, investing substantially in proprietary technologies and developing a robust pipeline of therapeutics aimed at addressing critical unmet medical needs across various domains such as ophthalmology, immunology, oncology, and rare diseases. Today, Regeneron makes its mark in the pharmaceutical industry primarily through its innovative product portfolio, comprised of renowned drugs like EYLEA, a leading treatment for retinal diseases, and Dupixent, a medication for atopic dermatitis and other allergic conditions. The company's revenue model relies heavily on the commercial success of these drugs, supported by strategic collaborations and partnerships with industry giants like Sanofi. Their success is driven by a commitment to leveraging cutting-edge technology platforms, such as the VelociSuite, which expedites drug discovery and development processes. Regeneron’s emphasis on precision and quality, coupled with an agile business model that adapts to health landscapes, allows it to maintain a competitive edge in a rapidly evolving industry while consistently delivering robust financial performance.

RGO Intrinsic Value
152.19 EUR
Undervaluation 15%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
28.9%
=
Operating Profit
4.1B
/
Revenue
14.1B
What is the Operating Margin of Regeneron Pharmaceuticals Inc?

Based on Regeneron Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 28.9%.

Back to Top